The Texas Medical Center Library

DigitalCommons@TMC
UT School of Public Health Dissertations (Open
Access)

School of Public Health

Spring 5-2019

PREDICTORS OF ON-TREATMENT MORTALITY OF PATIENTS
UNDERGOING PALLIATIVE RADIATION THERAPY: IMPROVING
THE QUALITY OF END-OFLIFE CANCER CARE
MATTHEW STEPHEN NING
UTHealth School of Public Health

Follow this and additional works at: https://digitalcommons.library.tmc.edu/uthsph_dissertsopen
Part of the Community Psychology Commons, Health Psychology Commons, and the Public Health
Commons

Recommended Citation
NING, MATTHEW STEPHEN, "PREDICTORS OF ON-TREATMENT MORTALITY OF PATIENTS UNDERGOING
PALLIATIVE RADIATION THERAPY: IMPROVING THE QUALITY OF END-OFLIFE CANCER CARE" (2019). UT
School of Public Health Dissertations (Open Access). 72.
https://digitalcommons.library.tmc.edu/uthsph_dissertsopen/72

This is brought to you for free and open access by the
School of Public Health at DigitalCommons@TMC. It has
been accepted for inclusion in UT School of Public Health
Dissertations (Open Access) by an authorized
administrator of DigitalCommons@TMC. For more
information, please contact
digitalcommons@library.tmc.edu.

COPYRIGHT
BY
MATTHEW S. NING, MD, MPH
2019

PREDICTORS OF ON-TREATMENT MORTALITY OF PATIENTS UNDERGOING
PALLIATIVE RADIATION THERAPY: IMPROVING THE QUALITY OF END-OFLIFE CANCER CARE
by

MATTHEW STEPHEN NING
M.D., Vanderbilt University School of Medicine, 2015

Presented to the Faculty of The University of Texas
School of Public Health
in Partial Fulfillment
of the Requirements
for the Degree of

MASTER OF PUBLIC HEALTH (M.P.H.)

THE UNIVERSITY OF TEXAS
SCHOOL OF PUBLIC HEALTH

Houston, Texas
May 2019

PREDICTORS OF ON-TREATMENT MORTALITY OF PATIENTS UNDERGOING
PALLIATIVE RADIATION THERAPY: IMPROVING THE QUALITY OF END-OFLIFE CANCER CARE

Matthew Stephen Ning, MD, MPH
The University of Texas
School of Public Health, 2019

CE/Thesis Chair: Dr. Rebecca Wells, PhD, MHSA

ABSTRACT
PURPOSE: Excessive medical treatment at end-of-life is an indicator of poor quality
care. While radiation therapy (RT) is effective for palliation, some patients die shortly
after or even during treatment. Any treatment that requires terminal patients to
spend significant time in the hospital setting contradicts palliative goals. This study
investigates patterns of end-of-life RT to inform quality improvement initiatives.
METHODS: All patients who died within 6 months of starting RT at a single large
academic cancer center between 2015 through 2018 were identified through our
institutional databases on an Institutional Review Board-approved protocol. Clinical
factors including age, treatment service, number of fractions, diagnosis, treatment
site, and treatment date were evaluated for associations with endpoints, 30-day
mortality and on-treatment mortality (mid-course), via logistic regression analysis.

RESULTS: 1,855 patients died within 6 months of initiating RT at our center. Of
these, 619 patients (33%) died within 30 days of starting RT, and were most
commonly treated by thoracic (26%), CNS (21%), and hematologic (13%) services.
Commonly treated sites included brain/spine (27%), bone (26%), and
mediastinum/thorax (10%). On logistic regression, both extended radiotherapy
prescription fractionation (>10 fractions/course) [OR 0.50, p<0.001] and advanced
stereotactic treatment technique (OR 0.61, p=0.002) were associated with
decreased likelihood of 30-day mortality, reflecting appropriate clinical rationale of
treating providers. Neither age (≥70 vs. <70 years) [OR 0.93, p=0.538] nor treatment
year (2017-2018 vs. 2015-2016) [OR 0.97, p=0.744] were associated with 30-day
mortality. Of the 619 patients, 142 (23%) died midway before completion of RT
course. Patients treated for emergent palliative mediastinal/thoracic indications (OR
11.4, p<0.001) were more likely to die midway through RT than those treated for
bone metastases. Notably, 2 out of every 3 patients treated for emergent palliative
mediastinal/thoracic indications (e.g. airway obstruction, hemoptysis) died ontreatment, comprising 27% of all on-treatment deaths (p<0.001).
CONCLUSION: Palliative RT remains an important therapeutic tool at the end-oflife. However, careful consideration of RT for emergent mediastinal/thoracic
indications should be used, given the high potential for on-treatment mortality. Taken
together, these data may help inform physician decision-making and facilitate
treatment consistent with palliative goals at the end-of-life.
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BACKGROUND
Literature Review
Excessive medical treatment at the end-of-life is an indicator of poor quality care [1].
Radiation therapy is routinely used for both curative and palliative cancer treatment.
Radiation can be an effective tool for palliation of symptoms arising from cancer,
such as pain from bone metastases or neurologic compromise from brain or spinal
metastases.
Although radiation is often well-tolerated with good outcomes, regardless of
goals of therapy, there are some patients that die soon after or even during
treatment. Furthermore, any treatment that requires dying patients to spend a
significant proportion of their final days in a hospital is contrary to the overall aims of
palliative care.
Nationwide, it is estimated that the majority of overall healthcare costs may be
attributed to care for patients within their last year of life [1-3]. Contributing to this
empirical pattern is the statistic that 1 in 5 patients who received radiation in their
final 30 days of life spend more than 10 of those days receiving treatment [1]. In
addition, among these patients, there has been a shift towards more advanced
radiation technologies, away from simpler (and most cost-effective) techniques [2-3].
These factors contribute to the finding that the costs of care for patients who
received radiotherapy at the end of life are higher than for those patients who did not
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[1]. Taken altogether, there is a need for quality improvement initiatives related to
palliative radiation delivered at the end-of-life.

Public Health Significance
As previously mentioned, there is a need for additional research into appropriate
indications for radiation at the end-of-life, to facilitate physician decision-making
regarding use of radiation consistent with palliative goals for patients with end-stage
cancer. For example, clinical guidelines could help oncologists reconsider treatment
or offer shorter (lower cost) treatment courses for uncomplicated cases while still
maintaining quality-of-life for such patients.
From a healthcare value framework, by defining indications for palliative
radiation (and reducing utilization in these scenarios), such guidelines would
promote the Institute for Healthcare Improvement (IHI) quality dimensions of
effectiveness, patient-centeredness, and safety (as some patients may have
hastened death due to excessive treatment courses). Furthermore, these guidelines
would be disseminated via publication to promote quality improvement on a national
population level.

Specific Research Aims and Objectives
In this study, we are first interested in quantitatively analyzing our collective
experience (as the largest national cancer center) in treating patients to identify any
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predictors of mortality in patients that are treated with radiation therapy, so that we
can better select optimal treatments in the future and provide quality care. Data from
this initial quantitative analysis will then be applied towards the following aims and
objectives related to the field of public health, which require a more comprehensive
interpretation in the context of the current literature:

1. By identifying recurring themes in these cases (particularly for patients who die
in-hospital away from their homes midway through treatment), these findings
would serve as a sort of immediate quality improvement initiative for our
Department of Radiation Oncology-- to communicate appropriate indications to
our 70 Radiation Oncology attending providers on the frontlines of oncological
care, defining those specific settings in which they should exercise particular
caution in deciding whether or not to offer treatment. With such guidelines, we
would expect to see these on-treatment mortality rates decrease (as well as the
overall numbers of patients getting aggressive treatments at the end-of-life).

2. We would then communicate these guidelines/criteria via publication, for
other providers across the country to refer to and apply within their Departments,
in an effort to improve healthcare quality on a national population level.
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3. Finally, we will interpret these findings from the perspective of a healthcare
value framework. If these treatments are prescribed gratuitously, they provide
questionable benefit in terms of patient comfort and quality-of-life. Furthermore,
they are associated with sometimes high absolute healthcare costs to the
patient/payer and provider, making them relatively low-value treatments.
Although cost-specific analyses are beyond the scope of this study, by defining
less-than-appropriate indications for palliative radiation (and reduce utilization in
these scenarios), we would promote the IHI healthcare quality dimensions of
effectiveness, patient-centeredness, and even safety (as some patients may
have hastened death due to "aggressive" treatment courses).
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METHODS
Study Design
In the initial quantitative data-generation portion of this study, the hospital and
radiation therapy charts of individual patients treated with radiation therapy (with
both curative and palliative intent) were reviewed and correlated to time of death.
Patients who died within 6 months of starting radiation therapy, including those
treated with definitive (curative) intent and those undergoing palliative treatment
were identified through the institutional database.
Once the cohort was established, individual clinical variables (e.g. age,
diagnosis, treatment site, hospitalization status, etc.) were analyzed and used to
determine if there was an ability to predict mortality during or after radiation therapy,
as per the statistical methods outlined in detail below.
Data from this initial quantitative analysis are being applied towards a more
comprehensive review of the data to address the aforementioned research aims and
objectives related to public health. Most notably, we will summarize our findings and
establish clinical guidelines for other practitioners to improve healthcare quality in
the palliative end-of-life setting at a national population level. Furthermore, we will
perform a detailed review and interpret these findings from the perspective of a
healthcare value framework within the setting of the current relevant literature.
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Study Setting
Department of Radiation Oncology at the University of Texas MD Anderson Cancer
Center (Houston, Texas)

Study Subjects
Patients treated at MD Anderson with radiation therapy from January 1, 2010 to
November 30, 2018 were included. All patients who received treatment and died
within 6 months of starting radiation, including patients treated with definitive
(curative) intent and patients who received palliative treatment, were included in the
analysis.

Sample Size Calculation and/or Study Power
There was no formally calculated sample size given the retrospective nature of this
review. We sought to capture the overall experience of treated patients at our
institution. However, initial review of the total dataset indicated that several hundred
patients met the eligibility criteria within the wide timeframe and were included in the
analysis. Despite its retrospective nature, these patient numbers increased the
likelihood of finding meaningful and statistically-significant findings.
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Data Collection
This study was IRB-approved by the University of Texas MD Anderson Cancer
Center (PA15-0639). For each identified patient, a retrospective chart review was
conducted within the electronic medical records (EPIC/OneConnect and
ClinicStation) for various clinical variables and mortality.

Data Analysis
Once the cohort was established, individual clinical variables (e.g. age, race,
diagnosis, treatment site, hospitalization status, etc.) were analyzed and used to
determine if there was an ability to predict mortality during or after radiation therapy.
Regarding statistical analyses, we applied logistic regression techniques to
determine the factors that predispose to mortality after radiation therapy via
associations of outcome to patient and treatment characteristics. These data can
help guide clinical practice guidelines which will be developed following review of the
data by an expert provider panel including the principal investigator.

Human Subjects and Safety Considerations
This protocol is a retrospective study which was IRB-approved by the University of
Texas MD Anderson Cancer Center (PA15-0639), including approval of a waiver of
informed consent, given the retrospective nature of this project. This protocol was
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also approved by the University of Texas Health Science Center Committee for
Protection of Human Subjects (HSC-SPH-18-1068).
Patient confidentiality was strictly maintained. The research involved no more
than minimal risk to the study subjects (i.e. risk of accidental release of personal and
or confidential information) because the patient history and treatment details of these
deceased patients were gathered from the hospital records. The waiver or alteration
did not adversely affect the rights, welfare, or subsequent clinical management. This
research could not practically be carried out without the waiver or alteration, given
that study subjects are deceased.
Cases were coded by anonymous study number using a key kept separate
from the database. Only the principal investigator of this study had access to patient
information, and only information relevant to this protocol was examined. All
protected health information was de-identified prior to releasing outcomes of the
study outside the research team. Strict patient confidentiality was maintained.
Data was stored on a password and firewall protected computer. A study
identifier was assigned to each case. A separate file containing the identifier and
subject names/MRN was maintained. Data was presented in aggregate. Data was
solely available to the principal investigator working on the project and kept on a
password-protected hard-drive with no patient specific information.
There are no paper records of data with personal identifiers. Patient identifiers
will be destroyed within 5 years of study completion. Until then, the database will be
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password protected on a limited access computer. Information will be destroyed
within 5 years after study publication.
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ABSTRACT
PURPOSE: Excessive medical treatment at end-of-life is an indicator of poor-quality
care. While radiation therapy (RT) is effective for palliation, some patients die shortly
after or even during treatment. Any treatment requiring terminal patients to spend
significant time in the hospital contradicts palliative goals. This study investigates
patterns of end-of-life RT at our institution to inform practice guidelines and quality
improvement initiatives.
MATERIALS AND METHODS: All patients who died within 6 months of starting RT
at our large academic cancer center between 2015 through 2018 were identified.
Clinical factors including age, diagnosis, inpatient status, number of fractions,
treatment date, service, and site were evaluated for associations with endpoints, 30day mortality and on-treatment (mid-course) mortality, via logistic regression.
RESULTS: A total of 1,855 patients died within 6 months of initiating RT. Of these,
619 died within 30 days, and were most commonly treated by thoracic (26%), CNS
(21%), and hematologic (13%) services. Commonly treated sites included
brain/spine (27%), bone (26%), and mediastinum/thorax (10%). Both extended
fractionation (>10/course) [OR 0.50, p<0.001] and stereotactic technique (OR 0.61,
p=0.002) were associated with decreased 30-day mortality, reflecting clinical
rationale of providers. Neither age (≥70 vs. <70 years) [p=0.538] nor treatment year
(2017-2018 vs. 2015-2016) [p=0.744] were associated with 30-day mortality. Of 619
patients, 142 (23%) died mid-course before completion. Patients treated for
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emergent mediastinal/thoracic indications (OR 11.4, p<0.001) were more likely to die
mid-course than those treated for bone metastases. Notably, 2 of every 3 patients
treated for emergent mediastinal/thoracic indications died on-treatment, comprising
27% of on-treatment deaths (p<0.001).
CONCLUSION: Palliative RT remains an important therapeutic tool at the end-oflife. However, careful consideration of RT for emergent mediastinal/thoracic
indications should be used, given high potential for on-treatment mortality. Taken
together, these data help inform physician decision-making and facilitate treatment
consistent with palliative goals.
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INTRODUCTION
Radiation therapy is an effective tool for palliation of symptoms arising from
cancer—such as pain from bone metastases [1,2], neurologic compromise from
spine or brain metastases [3], or bleeding from tumors [4]—and thus serves as an
important mainstay of end-of-life oncologic care. However, while RT is effective for
palliation, some patients may die during treatment, or too shortly afterwards to
realize palliative benefit; and any therapy requiring terminal patients to spend
significant time in the hospital contradicts palliative goals.
Excessive medical treatment at the end-of-life is an indicator of poor-quality
care [5,6], yet many patients continue to receive aggressive treatment in their last
days [7,8]. Along these lines, recent practice patterns for palliative RT have been
examined with scrutiny due to concerns for overutilization. An estimated 1 in 5
patients who receive RT in their final 30 days of life will spend >10 of those days
receiving treatment [5]; and among these patients, there has also been a shift
towards more advanced RT technologies, away from simpler (and more costeffective) techniques [9,10].
Much of this overutilization likely stems from the difficulty of accurately
predicting life expectancies for terminally ill patients. Physicians tend to misjudge
patient survival times [11–16], which can lead to overtreatment or extended
treatment courses disproportionate to patient life expectancies. Taken together,
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these practice trends call for more data to facilitate physician decision-making at the
end-of-life and improve the quality of palliative RT.
To help address this literature void, our study investigates the patterns of ontreatment and early post-treatment mortality for palliative RT at our large academic
cancer center. This investigation is the largest of its kind to date—encompassing all
tumor histologies, disease sites, and palliative indications—and thus improves upon
limited prior reports [17–19]. In addition to describing these patterns, we evaluate
specific clinical factors associated with early post-treatment and on-treatment
mortality, to inform subsequent practice guidelines and quality improvement
initiatives.

MATERIALS AND METHODS
Design, Patient Population, and Data Sources
All patients who died within 6 months of starting RT at a single large academic
cancer center between January 1, 2015 through December 31, 2018 were identified
through our institutional databases. Various clinical factors including age, treatment
service, number of fractions, diagnosis, treatment site, indication, inpatient status,
and treatment date were collected. This study protocol was approved by the
Institutional Review Board at the University of Texas MD Anderson Cancer Center
(PA15-0639).
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Statistical Analyses
The primary endpoints were on-treatment (mid-course) mortality and 30-day (early)
post-treatment mortality (computed from the start of RT). Univariate and
multivariable logistic regression analyses were conducted to identify potential
associations between clinical or treatment variables and mortality endpoints,
generating odds ratios (ORs) and 95% confidence intervals (CIs). Statistical
analyses were performed in SPSS version 23 (IBM Corp, release 2015; IBM SPSS
Statistics for Windows, Version 23.0; Armonk, NY: IBM Corp). For all statistical tests,
a p-value <0.05 was considered significant.

RESULTS
Patient and Treatment Characteristics
A total of 1,855 patients died within 6 months of initiating RT at our center. Of these,
619 patients (33%) died within 30 days of starting RT, and were most commonly
treated by thoracic (26%), CNS (21%), and hematologic (13%) services. Commonly
treated sites included brain/spine (27%), bone (26%), and mediastinum/thorax
(10%). Roughly 20% of hematologic patients were stem cell transplant candidates.

Factors Associated with Mortality within 30 Days of RT
On logistic regression, both extended radiotherapy prescription fractionation (>10
fractions/course) [OR 0.50, p<0.001] and advanced stereotactic treatment technique
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(OR 0.61, p=0.002) were associated with decreased likelihood of 30-day mortality,
reflecting appropriate clinical rationale of treating providers. Neither age (≥70 vs. <70
years) [OR 0.93, p=0.538] nor treatment year (2017-2018 vs. 2015-2016) [OR 0.97,
p=0.744] were associated with 30-day mortality.

Factors Associated with On-Treatment Mortality During RT
Of the 619 patients, 142 (23%) died midway before completion of RT course.
Patients treated for emergent palliative mediastinal/thoracic indications (OR 11.4,
p<0.001) were more likely to die midway through RT than those treated for bone
metastases. Notably, 2 out of every 3 patients treated for emergent palliative
mediastinal/thoracic indications (e.g. airway obstruction, hemoptysis) died ontreatment, comprising 27% of all on-treatment deaths (p<0.001). Of note, 80% of all
patients who died on-treatment were inpatients, while 82% of the
thoracic/mediastinum patients were inpatient.

DISCUSSION
In this study investigating patterns of mid-treatment and early post-treatment
mortality in palliative RT, our pertinent findings were as follows: (a) out of all patients
who died within 6 months of initiating RT at our institution, one-third died within the
first 30 days following RT, and a quarter of those patients died on-treatment; (b)
inpatient status was significantly associated with mid-course mortality, with 80% of
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on-treatment deaths occurring in hospitalized patients; and finally (c) patients treated
for emergent mediastinal/thoracic indications were more likely to die on treatment,
with 2 of every 3 patients dying before completion of RT.
The high proportion of patients dying shortly after or even during palliative RT
at our institution is consistent with prior reports of RT utilization at the end-of-life
[5,17]. This discrepancy likely stems from provider tendency to overestimate survival
times for terminally ill patients, which leads to difficulty in tailoring palliative regimens
appropriately to limited life expectancies [11–16]. As such, these data call for
additional efforts focused on improving life expectancy assessments. Reassuringly,
our study demonstrated lower utilization of extended fraction prescriptions (>10
fractions/course) and advanced stereotactic techniques in patients who died within
30 days of RT. This finding is consistent with the ASTRO Choosing Wisely
guidelines for end-of-life treatment, which advocate for shorter palliative courses for
patients with limited prognoses, as multiple studies have demonstrated the noninferiority of shorter regimens [2,20,21].
With regard to clinical prognostic factors, inpatient hospitalization status
during RT was significantly associated with on-treatment mortality among our patient
population. This finding is corroborated by prior reports of palliative RT which
demonstrate worse survival outcomes for patients evaluated as inpatient consults
[17,22], and for those with advanced disease experiencing an unplanned admission
for symptom control [18] or an intensive care unit admission [19]. Similarly, Grade et
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al. similarly demonstrated higher rates of stopping treatment early among inpatients
[18]. Taken together, these data support inpatient RT as a clinical prompt for
comprehensive palliative care and hospice referral, if not already present. Shorter
hypo-fractionated treatment courses are also preferred in this setting, given the poor
performance statuses and prognoses of such inpatients.
In addition to inpatient status, our study found emergent mediastinal/thoracic
indications to be highly associated with on-treatment mortality, with 2 out of every 3
patients dying before completion of RT. In general, many patients with metastatic or
incurable locally advanced lung cancers can benefit from palliative thoracic RT to
alleviate tumor-related symptoms such as hemoptysis, cough, and chest pain [23–
26]; and even high-dose rate endobronchial brachytherapy is efficacious for
palliating airway obstruction or hemoptysis due to endobronchial tumors [25,27].
However, our data indicate that the majority of emergent mediastinal/thoracic cases
(e.g. severe hemoptysis or bronchial obstruction in the inpatient setting) are likely to
die mid-treatment prior to RT completion. These findings are consistent with those of
Grade et al., who demonstrated airway compromise as a serious indication
associated with worse survival [18]. Therefore, while palliative RT can be safe and
efficacious for a range of thoracic indications, providers should exercise caution for
emergent mediastinal/thoracic cases, given the high likelihood of on-treatment
mortality in this setting.
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To summarize, this study analyzes the patterns of on-treatment and early
post-treatment mortality of patients undergoing palliative RT at a large academic
cancer center. The major limitation of this work is its single-institution, retrospective
nature, reflecting practice patterns specific to our provider group. However, our study
benefits from being the largest series of its kind to date and encompassing a wide
range of palliative indications and sites, thereby improving upon previous reports
[17–19]. Taken together, these data can inform practice guidelines and quality
improvement initiatives aimed at optimizing end-of-life care for terminally-ill patients
with cancer.
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CONCLUSION
To summarize, this study analyzes the patterns of on-treatment and early posttreatment mortality of patients undergoing palliative RT at a large academic cancer
center. Palliative RT remains an important therapeutic tool at the end-of-life.
However, careful consideration of RT for emergent mediastinal/thoracic indications
should be used, given the high potential for on-treatment mortality. Taken together,
these data may help inform physician decision-making and facilitate treatment
consistent with palliative goals at the end-of-life.
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